Avid Bioservices, Inc. (CDMO) News
Filter CDMO News Items
CDMO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CDMO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CDMO News From Around the Web
Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and AmpersandAvid Urges Stockholders to Vote FOR the Pending Transaction TODAYTUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today posted an investor presentation in connection with its pending transaction with GHO Ca |
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and AmpersandTUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously an |
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing TransactionFiles Definitive Proxy Statement and Mails Letter to StockholdersTUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has commenced mailing definitive proxy materials and a letter to sto |
Avid Bioservices: Fiscal Q2 Earnings SnapshotTUSTIN, Calif. AP) — Avid Bioservices Inc. CDMO) on Tuesday reported a loss of $17.4 million in its fiscal second quarter. |
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: “We delivered solid results in a comp |
Avid Bioservices, Inc. (CDMO): A Bull Case TheoryWe came across a bullish thesis on Avid Bioservices, Inc. (CDMO) on Twitter by northeasternsvf. In this article, we will summarize the bulls’ thesis on CDMO. Avid Bioservices, Inc. (CDMO)’s share was trading at $12.20 as of Nov 13th. CDMO’s trailing and forward P/E were 9.41 and 88.50 respectively according to Yahoo Finance. Avid Bioservices, Inc., a […] |
Avid Bioservices to be Acquired in $1.1 Billion DealAvid Bioservices ( (CDMO) ) just unveiled an announcement. Avid Bioservices, a biologics contract development and manufacturing organization, is set to be acquired by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion all-cash transaction. Shareholders will receive $12.50 per share, representing a premium to recent trading prices. The merger is expected to close in early 2025, subject to customary conditions and approvals. This acquisition aims to leverage the expertise and ca |
GHO and Ampersand Capital to acquire Avid BioservicesThe definitive merger agreement stipulates that GHO and Ampersand will purchase all outstanding shares of Avid. |
Avid Bioservices to Go Private in $1.1 Billion DealAvid Bioservices Chief Executive Nick Green said the company’s board considered several options before determining to move forward as a private company under new owners. |
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion TransactionTUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) today announced they have entered into a definitive merge |